Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
Altimmune management will host a conference call for investors beginning at
Conference Call Information:
Date: | |
Time: | |
877-423-9813 | |
International Dial-in: | 201-689-8573 |
Conference ID: | 13719206 |
Webcast: | http://public.viavid.com/index.php?id=144634 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Will Brown | |
Chief Financial Officer | Sr. Dir, Investor Relations |
Phone: 240-654-1450 | Phone : 410-474-8200 |
wbrown@altimmune.com | sjurchison@altimmune.com |
Source: Altimmune, Inc.